ArticleFrontiers in pharmacology2022

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.

Pan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.